Letter to the Editor - Devices regulation in the UK
This article was originally published in Clinica
Executive Summary
Two weeks ago, we printed a feature in which some of the UK devices sector's key players decried the lower regulatory profile of their industry in the year and a half since devices and pharma regulation were merged under the all-embracing Medicines and Healthcare products Regulatory Agency (MHRA). On pages 4-8 of Clinica No 1133, interested and concerned parties - MP Ian Gibson, BIVDA (for the diagnostics industry), and the BHTA among them - bemoaned the decision not to install a dedicated head of UK devices regulation. Some observers considered that credible reasons for this were not given at the inception of the MHRA, and are no less reassured 18 months later. We approached MHRA chief executive Professor Kent Woods for his comments on the debate that has emerged, but internal MHRA procedures prevented him from talking to us. Here, he gives a written response.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.